Cell

10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year

Wednesday, December 1, 2021 - 10:06pm

This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.

Key Points: 
  • This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.
  • "We're honored and humbled to be consistently recognized by The Scientist for our culture of innovation and strong cadence of technological advancement.
  • To see the full list of The Scientist's 2021 Top 10 Innovations, please visit www.the-scientist.com/features/2021-top-10-innovations-69438 .
  • 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.

New Assembly Approach Generates Most Complex Stomach Organoids to Date

Wednesday, December 1, 2021 - 4:00pm

And the approach used to produce these multi-layered stomach organoids also can be used to make more-complex versions of other lab-grown organs.

Key Points: 
  • And the approach used to produce these multi-layered stomach organoids also can be used to make more-complex versions of other lab-grown organs.
  • "This advance in tissue engineering is important because we can now assemble complex organ tissues from separately derived components, similar to an assembly line approach," says corresponding author James Wells, PhD.
  • The findings were published Dec. 1, 2021 in Cell Stem Cell by Wells and lead author Alexandra Eicher, PhD.
  • In addition to demonstrating a three-layered approach for developing stomach organoids, the team also applied a similar approach to make a more sophisticated esophageal organoid.

Dr. Aletta Schnitzler Joins TurtleTree as Chief Scientific Officer

Wednesday, December 1, 2021 - 3:00pm

DAVIS, Calif. and SINGAPORE, Dec.1, 2021 /PRNewswire/ --Cell-based nutrition companyTurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO).

Key Points: 
  • DAVIS, Calif. and SINGAPORE, Dec.1, 2021 /PRNewswire/ --Cell-based nutrition companyTurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO).
  • Prior to joining TurtleTree, Aletta was with MilliporeSigma for over 10 years.
  • There, Aletta led a scientific and engineering team in creating cutting-edge technologies for the manufacturing of cultured meat.
  • As TurtleTree's CSO, Dr. Schnitzler will communicate TurtleTree's scientific interests to internal and external stakeholders.

Dr. Aletta Schnitzler Joins TurtleTree as Chief Scientific Officer

Wednesday, December 1, 2021 - 3:00pm

DAVIS, Calif. and SINGAPORE, Dec.1, 2021 /PRNewswire/ --Cell-based nutrition companyTurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO).

Key Points: 
  • DAVIS, Calif. and SINGAPORE, Dec.1, 2021 /PRNewswire/ --Cell-based nutrition companyTurtleTree welcomes Dr. Aletta Schnitzler as its new Chief Scientific Officer (CSO).
  • Prior to joining TurtleTree, Aletta was with MilliporeSigma for over 10 years.
  • There, Aletta led a scientific and engineering team in creating cutting-edge technologies for the manufacturing of cultured meat.
  • As TurtleTree's CSO, Dr. Schnitzler will communicate TurtleTree's scientific interests to internal and external stakeholders.

NDRI Elects Paul M. Lieberman, Ph.D., to Board of Directors

Wednesday, December 1, 2021 - 2:14pm

Philadelphia-based National Disease Research Interchange (NDRI) announces the election of Paul M. Lieberman, Ph.D., to its Board.

Key Points: 
  • Philadelphia-based National Disease Research Interchange (NDRI) announces the election of Paul M. Lieberman, Ph.D., to its Board.
  • (Photo: Business Wire)
    Lieberman is a molecular virologist and an expert in gene expression and regulation at Wistars Cancer Center.
  • Mary J.C. Hendrix, Ph.D., Chair of the NDRI Board and President of Shepherd University, shared, We are thrilled to welcome Dr. Lieberman to the NDRI Board of Directors.
  • The National Disease Research Interchange (NDRI) is the nations leading source of human tissues, cells and organs for scientific research.

StoreDot, the Extreme Fast Charging Battery Pioneer, Develops Technology for Self-Repairing Cells Allowing Longer Battery Life and Better Electric Vehicle Performance

Wednesday, December 1, 2021 - 2:00pm

Alongside the development of our leading silicon-dominant XFC cells, StoreDot is committed to broadening its portfolio to advance the entire battery eco-system.

Key Points: 
  • Alongside the development of our leading silicon-dominant XFC cells, StoreDot is committed to broadening its portfolio to advance the entire battery eco-system.
  • This latest patented technology is a unique way of repairing individual cells, or groups or cells, when they are in operation is a novel advancement to self-repairing electric vehicles.
  • This approach is truly transformative with huge real-world benefits for electric vehicle owners, improving performance, safety and the longevity of their vehicles.
  • StoreDot is a pioneer and leader of extreme fast charging (XFC) batteries that overcome the critical barrier to mainstream EV adoption range and charging anxiety.

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

Wednesday, December 1, 2021 - 2:00pm

These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).

Key Points: 
  • These are the first comprehensive data showing that INKmune-mediated priming generates NK cells with memory-like phenotype (mlNK).
  • These in vitro data have been replicated in the first patient treated with three, weekly doses of INKmune for high risk MDS.
  • Details of the presentations are as follows:
    Natural killer (NK) cells are innate lymphocytes that target virus-infected and tumor cells.
  • Their unique phenotypic and gene expression signatures suggest a novel and distinct form of memory-like NK cell governed by tumor-specific signaling pathways.

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

Wednesday, December 1, 2021 - 1:30pm

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.
  • We are fortunate to have an ideal partner in UpScriptHealth, a pioneer in online healthcare prescribing with a nationwide network of telemedicine physicians, as we look to expand the EsoGuard Telemedicine Program and Lucid Test Center network regionally and nationally.
  • Now, patients who respond to direct-to-consumer engagements can request video telemedicine evaluation through the EsoGuard Telemedicine Program by contacting 1-888-FOODTUBE or registering at www.EsoGuardConsultation.com .
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China

Wednesday, December 1, 2021 - 12:40pm

SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its China Initiative has been accepted by the Roche Accelerator .

Key Points: 
  • SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its China Initiative has been accepted by the Roche Accelerator .
  • Launched earlier this year, the accelerator is Roches first in-house accelerator globally and further establishes its long-term commitment to Shanghai and China.
  • Collaboration with the Roche Accelerator will support early strategic planning and potential China-based activities for the SQZ China Initiative.
  • Roche has been a strategic partner with the company since 2015 and has an ongoing collaboration with SQZ on the SQZ APC oncology program globally.

ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers

Wednesday, December 1, 2021 - 12:30pm

Previously known as ZetaFuse, ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.

Key Points: 
  • Previously known as ZetaFuse, ZetaMet is a synthetic, small-molecule, inductive biologic technology being developed to target and resolve metastatic bone lesions while inhibiting future tumor growth and regenerating bone.
  • The combination technology has, thus far, in preclinical studies, demonstrated its ability to resolve existing metastatic bone lesions, inhibit pain and stimulate targeted bone regeneration.
  • Bone metastases are common among cancer patients and occur when cells from the primary cancerous tumor relocate to the bone.
  • Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions.